We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

233 hedge funds and large institutions have $2.09B invested in BioCryst Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 67 increasing their positions, 71 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more call options, than puts

Call options by funds: $92M | Put options by funds: $34.8M

138% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 21

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

29% more capital invested

Capital invested by funds: $1.62B → $2.09B (+$470M)

13% more funds holding

Funds holding: 206 → 233 (+27)

3.21% more ownership

Funds ownership: 66.01% → 69.22% (+3.2%)

6% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 71

Holders
233
Holders Change
+27
Holders Change %
+13.11%
% of All Funds
3.68%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
50
Increased
67
Reduced
71
Closed
21
Calls
$92M
Puts
$34.8M
Net Calls
+$57.2M
Net Calls Change
+$18M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$72.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$60.9M
3
Victory Capital Management
Victory Capital Management
Texas
+$49.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$37.2M
5
ACA
Avoro Capital Advisors
New York
+$30.1M

Top Sellers

1
SCM
Sarissa Capital Management
Connecticut
-$42.5M
2
HM
HealthCor Management
New York
-$34.5M
3
SI
Sofinnova Investments
California
-$20.9M
4
Two Sigma Investments
Two Sigma Investments
New York
-$16.4M
5
BCPEMI
Bain Capital Public Equity Management II
Massachusetts
-$14.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$229M -$11M -685,420 -5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$215M +$60.9M +3,794,135 +40%
BBA
3
Baker Bros. Advisors
New York
$207M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$137M +$72.5M +4,518,210 +116%
State Street
5
State Street
Massachusetts
$121M -$12.6M -786,277 -10%
PAMS
6
Pictet Asset Management (Switzerland)
Switzerland
$83M +$828K +51,639 +1%
Fisher Asset Management
7
Fisher Asset Management
Washington
$64.8M -$1.77M -110,229 -3%
RM
8
RP Management
New York
$62.5M – – –
Victory Capital Management
9
Victory Capital Management
Texas
$57.5M +$49.9M +3,112,255 +705%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$53.4M +$1.02M +63,502 +2%
Artisan Partners
11
Artisan Partners
Wisconsin
$46.2M +$2.81K +175 +0%
N
12
Nuveen
North Carolina
$38.8M +$1.54M +96,290 +4%
Loomis, Sayles & Company
13
Loomis, Sayles & Company
Massachusetts
$38.3M +$14.7M +919,104 +64%
Lord, Abbett & Co
14
Lord, Abbett & Co
New Jersey
$37.7M +$37.2M +2,318,016 New
ACA
15
Avoro Capital Advisors
New York
$30.5M +$30.1M +1,875,000 New
Stifel Financial
16
Stifel Financial
Missouri
$30.1M +$13.1K +818 +0%
Northern Trust
17
Northern Trust
Illinois
$29.3M -$980K -61,110 -3%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$28.8M -$6.11M -380,900 -18%
OIM
19
Oracle Investment Management
Connecticut
$28M +$802K +50,000 +3%
BNP Paribas Asset Management
20
BNP Paribas Asset Management
France
$27.1M -$3.62M -225,904 -12%
SCM
21
Sarissa Capital Management
Connecticut
$22.6M -$42.5M -2,648,810 -66%
Charles Schwab
22
Charles Schwab
California
$21.9M +$1.16M +72,026 +6%
Goldman Sachs
23
Goldman Sachs
New York
$20.7M +$7.38M +459,965 +57%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$20.2M -$12.1M -756,233 -38%
Alkeon Capital Management
25
Alkeon Capital Management
New York
$19.3M +$19.1M +1,187,845 New
1
2 3 4 5

BCRX Hedge Fund Activity: Q1 2022 in Review

233 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2022, worth a combined $2.09B — up 29% from $1.62B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new BCRX positions and 21 closed out — a net gain of 29 holders — while 67 added to existing stakes and 71 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $72.5M. The largest seller was Sarissa Capital Management, cutting an estimated $42.5M.

  • 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2022, up from 206 in Q4 2021.
  • Funds reported $2.09B of BioCryst Pharmaceuticals stock for Q1 2022, up 29% quarter-over-quarter.
  • 50 funds opened new BioCryst Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +29 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2022 was Fidelity Investments, an estimated $72.5M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2022 was Sarissa Capital Management, an estimated $42.5M sold.

Based on aggregated 13F filings for Q1 2022.